Pfizer CEO Albert Bourla Receives 24 Phantom Shares

What Happened
Albert Bourla, Pfizer’s Chairman & CEO, received an award of 24 units representing phantom shares on July 15, 2026. The filing reports an acquisition (code A) at $24.82 per unit for a total reported value of $596. This was an award (derivative unit grant), not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-07-15; reported on Form 4 filed 2026-07-16 (appears timely).
• Instrument and amount: 24 units (phantom shares) at $24.82 each; total value ≈ $596.
• Shares owned after transaction: Not disclosed in this filing.
• Footnotes: F1 — each unit equals one phantom share; F2 — units were issued under the Pfizer Nonfunded Deferred Compensation and Supplemental Savings Plan, are cash‑settled after separation from service, and may be moved into an alternative investment account at any time.
• Transaction code: A = Grant/Award (derivative).

Context
These are deferred compensation units (phantom shares) rather than actual common stock and are settled in cash upon the reporting person’s separation from service. Awards like this are common components of executive compensation and do not represent an immediate buy or sell of company stock.